CurrentCignaPolicy N/A

Oncology - Sunitinib Prior Authorization Policy

Defines Cigna's prior authorization requirements and medical necessity criteria for prescription sunitinib (Sutent and generic) for oncology indications for adult patients.

Policy Summary

PayerCigna

PolicyOncology - Sunitinib Prior Authorization Policy

Policy CodePolicy N/A

Change TypeDeletion of adjuvant RCC indicationnomenclature clarification

Effective DateN/A

Next Review DateJul 23, 2025

Key ActionSubmit prior authorization documenting that the patient meets the listed medical necessity criteria for the requested sunitinib indication and duration.

SourceLink

POLICY UPDATE CHANGES

Deleted criteria for approval of sunitinib as adjuvant therapy after nephrectomy for renal cell carcinoma.

Changed naming for Hürthle cell carcinoma to oncocytic carcinoma (formerly Hürthle cell carcinoma) under differentiated thyroid cancer examples.

11+indications

1 yearapproval duration

≥18minimum age

NCCN referencedguideline source

Medical Necessity and Coverage Criteria

Policy Summary

PayerCigna

PolicyOncology - Sunitinib Prior Authorization Policy

Policy CodePolicy N/A

Change TypeDeletion of adjuvant RCC indicationnomenclature clarification

Effective DateN/A

Next Review DateJul 23, 2025

Key ActionSubmit prior authorization documenting that the patient meets the listed medical necessity criteria for the requested sunitinib indication and duration.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

FDA-Approved Indications

Covered when ALL of the following are met for each FDA-approved indication (approval duration = 1 year):

GIST (FDA-approved): Patient is ≥ 18 years of age AND patient meets ONE of the following: patient has tried imatinib OR patient has succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor.age >= 18

Approve for 1 year

Pancreatic neuroendocrine tumor (FDA-approved): Patient is ≥ 18 years of age AND patient has advanced or metastatic disease.age >= 18

Approve for 1 year

Renal cell carcinoma (FDA-approved): Patient is ≥ 18 years of age AND patient has relapsed or advanced disease.age >= 18

Approve for 1 year

Other Uses with Supportive Evidence

Covered when ALL of the following are met for each listed supportive-evidence indication (approval duration = 1 year):

Bone cancer - recurrent chordoma: Patient is ≥ 18 years of age AND patient has recurrent chordoma.age >= 18

Approve for 1 year

Meningioma: Patient is ≥ 18 years of age AND patient has recurrent or progressive disease.age >= 18

Approve for 1 year

Myeloid/lymphoid neoplasms with eosinophilia: Patient is ≥ 18 years of age AND patient has eosinophilia AND the tumor has an FLT3 rearrangement.age >= 18

Approve for 1 year

Sunitinib (Sutent and generic) is considered not medically necessary for any uses not explicitly listed in this policy. The list of covered indications and the specific medical necessity criteria above define the circumstances under which sunitinib may be authorized; the policy will be updated as new published data become available.

Adjuvant use of sunitinib after nephrectomy for renal cell carcinoma has been removed from the approval criteria and is not covered due to a low level of supporting evidence (NCCN category 3). Other unlisted uses remain not medically necessary and the criteria will be revised if new evidence emerges.

Requirement	Examples / Notes
Member must have tried at least one prior systemic chemotherapy regimen for thymic carcinoma
Examples of systemic chemotherapy regimens include one or more of: carboplatin; paclitaxel; cisplatin; doxorubicin; cyclophosphamide; etoposide.

What Providers Must Do / Billing Considerations

Prior Authorization

Prior Authorization Required

Prior Authorization Required: Prior authorization is recommended for prescription benefit coverage of sunitinib (Sutent®/sunitinib malate). Approvals are issued for the durations noted in the policy (generally 1 year for the listed indications).

Prior authorization is recommended/required for sunitinib; approvals provided for the duration specified (typically 1 year for approved indications).

Step Therapy

Step Therapy / Prior Therapy Requirements

Step therapy / prior therapy requirements: Some indications require documentation of a trial of prior therapy before approval. For example, Gastrointestinal Stromal Tumor (GIST) requires a trial of imatinib unless the GIST is succinate dehydrogenase (SDH)-deficient; certain other indications require prior systemic chemotherapy.

GIST: trial of imatinib required unless SDH-deficient.
Thymic carcinoma: patient must have tried ≥1 systemic chemotherapy regimen (examples include carboplatin, paclitaxel, cisplatin, doxorubicin, cyclophosphamide, etoposide).

Documentation Required

Required Documentation for Prior Authorization

Required documentation: Prior authorization requests must include documentation demonstrating the patient meets the medical necessity criteria listed in this policy — including age, diagnosis-specific requirements, prior therapy/trial history when applicable, and evidence of advanced/relapsed/metastatic disease where required. Requests lacking sufficient documentation to confirm criteria may be delayed or denied.

Include patient age and specific diagnosis.
Document prior therapy trials and dates (e.g., imatinib for GIST; systemic chemotherapy for thymic carcinoma).
Provide pathology/genetic testing if relevant (e.g., SDH-deficient status, FLT3 rearrangement).
Document disease status (advanced, metastatic, relapsed, recurrent or progressive) as applicable.

Denial Risk

Denial Risk for Non‑Covered Codes

Denial Risk for Non‑Covered Codes or Incomplete Criteria: Requests submitted with diagnoses, procedure, or billing codes that are not covered under this policy — or without documentation that the patient meets the listed coverage criteria — will be denied as not covered. Providers must bill using the most appropriate codes as of the date of service and ensure the submitted benefit plan allows coverage for the requested service.

Claims submitted without covered diagnosis or procedure codes under this coverage policy will be denied.
Ensure coding aligns with the applicable benefit plan document; plan-specific exclusions may apply.

Line of Therapy Criteria

first-line

First-line use (kidney cancer): Sunitinib is requested as a first-line systemic therapy for renal cell carcinoma in an adult patient (≥ 18 years) consistent with NCCN recommendations for clear cell or non-clear cell histology.

Per NCCN, may be used as first-line; document histology and stage

second-line

Second-line use (GIST): Sunitinib is requested as second-line therapy for gastrointestinal stromal tumor (adult patient ≥ 18 years) after progression on or intolerance to imatinib, unless the GIST is SDH-deficient.

Preferred second-line per NCCN; document prior imatinib trial or SDH-deficient status

Biomarker and Molecular Test Requirements

FLT3 rearrangement — biomarker requirement

BiomarkerFLT3 rearrangement

Required for indicationMyeloid/lymphoid neoplasms with eosinophilia

Age requirementPatient is ≥ 18 years of age

Coverage action when presentApprove for 1 year if eosinophilia and FLT3 rearrangement are documented

SDH-deficient status — biomarker requirement

BiomarkerSDH-deficient status (succinate dehydrogenase-deficient)

Applies toGastrointestinal stromal tumor (GIST)

Effect on prior therapy requirementAllows sunitinib without a prior trial of imatinib when SDH-deficient GIST is documented

Age requirementPatient is ≥ 18 years of age

Background

Sunitinib is an oral multi‑kinase inhibitor approved by the FDA in adults for specific oncology indications. Indications described in the policy include treatment of gastrointestinal stromal tumor (GIST) after imatinib progression or intolerance, advanced pancreatic neuroendocrine tumors, and advanced or relapsed renal cell carcinoma, among other tumor types referenced in guideline sources. Prior authorization is recommended for coverage and approvals are issued for 1 year when the listed medical necessity criteria are met.

OpenPayer

Oncology - Sunitinib Prior Authorization Policy

Medical Necessity and Coverage Criteria

What Providers Must Do / Billing Considerations

Line of Therapy Criteria

Biomarker and Molecular Test Requirements

Definitions and Key Terms

Background